Anavex Life Sciences Corp.: financial statements

AVXLNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.59

November 20, 2026Market cap $53M

What Ploutos Investor adds for Anavex Life Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 80% since Aug 28, 2026, when the 10-Q these figures come from was filed ($2.99 then, $0.59 on Nov 20, 2026). The figures date from before that move.10-Q
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2023–FY2025 fiscal years

Click a line to see it on the chart.

Operating income

LineFY2023FY2024FY2025Average a year
Operating income -$56M-$53M-$51M
Net income -$48M-$43M-$46M
Earnings per share -$0.60-$0.52-$0.54
Earnings per share, basic -$0.60-$0.52-$0.54

Financial statements

AVXL's revenue, profits and cash flows from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Anavex Life Sciences's filings show?

These are Anavex Life Sciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about AVXL's financials

Didn't find what you were looking for?

Ask us
How much debt does AVXL have?

On September 30, 2025 Anavex Life Sciences had total assets of $104M, debt of – and shareholders' equity of $95M.

Where are the figures from?

From Anavex Life Sciences Corp.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.